Lista de obras - David Fiorentino - Dominio Público Uruguay

2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects

scientific article published on 01 November 2017

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri

artículo científico publicado en 2017

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri

artículo científico publicado en 2017

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients ⬇️

artículo científico publicado el 23 de febrero de 2013

A pilot study of etanercept treatment for pemphigus vulgaris

artículo científico publicado en 2011

A pilot trial of rituximab in the treatment of patients with dermatomyositis

scientific article published on 01 June 2007

Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey

artículo científico publicado en 2013

Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer–myositis connection ⬇️

artículo científico publicado el 1 de febrero de 2012

Clinical factors associated with cutaneous histopathologic findings in dermatomyositis

scientific article published on 03 April 2019

Clinical presentation and evaluation of dermatomyositis

artículo científico publicado en 2012

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

artículo científico publicado en 2012

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

artículo científico publicado en 2008

Conditioned pharmacotherapeutic effects: a preliminary study.

artículo científico publicado en 2009

Consensus guidelines for the management of plaque psoriasis.

artículo científico publicado en 2012

Dermatomyositis

scientific article published on 01 January 2008

Dermatomyositis autoantibodies: clinical markers of patients past, present, and future

artículo científico publicado en 2011

Digital ulcers in patients with systemic sclerosis

artículo científico publicado en 2005

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis

artículo científico publicado en 2011

Genomic signatures characterize leukocyte infiltration in myositis muscles.

artículo científico publicado en 2012

Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients

artículo científico publicado en 2011

Imatinib in the treatment of nephrogenic systemic fibrosis

artículo científico publicado en 2008

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

artículo científico publicado en 2013

Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases

artículo científico publicado en 2013

Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases

artículo científico publicado en 2012

International consensus for a definition of disease flare in lupus.

artículo científico publicado en 2010

Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil

artículo científico publicado en 2006

Localized cutaneous fibrosing disorders

artículo científico

Localized scleroderma and systemic sclerosis: is there a connection?

artículo científico publicado en 2007

Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument

artículo científico publicado en 2009

Molecular framework for response to imatinib mesylate in systemic sclerosis.

artículo científico publicado en 2009

Molecular profiling to diagnose a case of atypical dermatomyositis.

artículo científico publicado en 2013

Muir-Torre syndrome: confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions

artículo científico publicado en 2004

Mycophenolate mofetil

artículo científico publicado en 2007

Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis

artículo científico publicado en 2007

Pathogenesis of dermatomyositis: role of cytokines and interferon.

artículo científico publicado en 2011

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

artículo científico publicado en 2011

Quality of life in dermatomyositis

artículo científico publicado en 2011

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

artículo científico publicado en 1992

Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle

artículo científico publicado en 2008

Skin disease in dermatomyositis

artículo científico publicado en 2012

Successful use of rituximab for cutaneous vasculitis

artículo científico publicado en 2006

Systemic and localized scleroderma

artículo científico publicado en 2006

The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes

artículo científico publicado en 2011

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study

artículo científico publicado en 2011

Treatment of recalcitrant eosinophilic cellulitis with adalimumab.

artículo científico publicado en 2012

Treatment recommendations for psoriatic arthritis.

scientific article published on 24 October 2008

Update on cutaneous vasculitis

artículo científico publicado en 2006

Lista de obras de David Fiorentino

2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients ⬇️

A pilot study of etanercept treatment for pemphigus vulgaris

A pilot trial of rituximab in the treatment of patients with dermatomyositis

Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey

Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer–myositis connection ⬇️

Clinical factors associated with cutaneous histopathologic findings in dermatomyositis

Clinical presentation and evaluation of dermatomyositis

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis

Conditioned pharmacotherapeutic effects: a preliminary study.

Consensus guidelines for the management of plaque psoriasis.

Dermatomyositis

Dermatomyositis autoantibodies: clinical markers of patients past, present, and future

Digital ulcers in patients with systemic sclerosis

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis

Genomic signatures characterize leukocyte infiltration in myositis muscles.

Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients

Imatinib in the treatment of nephrogenic systemic fibrosis

Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases

Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases

International consensus for a definition of disease flare in lupus.

Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil

Localized cutaneous fibrosing disorders

Localized scleroderma and systemic sclerosis: is there a connection?

Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument

Molecular framework for response to imatinib mesylate in systemic sclerosis.

Molecular profiling to diagnose a case of atypical dermatomyositis.

Muir-Torre syndrome: confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions

Mycophenolate mofetil

Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis

Pathogenesis of dermatomyositis: role of cytokines and interferon.

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

Quality of life in dermatomyositis

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

Similar topology of injury to keratinocytes and myofibres in dermatomyositis skin and muscle

Skin disease in dermatomyositis

Successful use of rituximab for cutaneous vasculitis

Systemic and localized scleroderma

The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes

The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study

Treatment of recalcitrant eosinophilic cellulitis with adalimumab.

Treatment recommendations for psoriatic arthritis.

Update on cutaneous vasculitis